



Retirement of Director Prof Peter Colman

Melbourne, Australia; 12 February 2008: Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) wishes to advise that Prof Peter Colman has elected to retire as a director of the company, effective from close of business on 11 February 2008.

Prof Colman was a founding member of Starpharma and has served on the Board for more than 10 years as both a director and a member of its Research Committee. In announcing his retirement, Prof Colman said: "I have enjoyed participating in the growth and maturation of Starpharma over the past 10 years – sharing the achievements and working through the challenges."

"Starpharma has several commercial deals in place and its lead product VivaGel[®] is progressing well along the clinical path towards product registration. I remain convinced of the significant potential of Starpharma's dendrimer technology for wide-ranging applications in the pharmaceutical and life sciences," Prof Colman said.

Starpharma Chairman Peter Bartels said: "Starpharma has been fortunate in having such an eminent scientist as Peter Colman on its board. His scientific knowledge, management expertise and previous experience as a founding director of Biota Holdings have been invaluable in helping to guide Starpharma from a start-up biotech to an established international dendrimer nanotechnology company."

Prof Colman will continue to act as a scientific advisor to the company.

The Board expresses its appreciation of Prof Colman's contribution to Starpharma and wishes him well for the future.

About Starpharma

Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is a world leader in the development of dendrimer nanotechnology for pharmaceutical, life-science and other applications. SPL is principally composed of two operating companies, Starpharma Pty Ltd in Melbourne, Australia and Dendritic Nanotechnologies, Inc in Michigan, USA. Products based on SPL's dendrimer technology are already on the market in the form of diagnostic elements and laboratory reagents.

The Company's lead pharmaceutical development product is VivaGel[®] (SPL7013 Gel), a vaginal microbicide designed to prevent the transmission of STIs, including HIV and genital herpes.

In the wider pharmaceutical field Starpharma has specific programs in the areas of Drug Delivery and Drug Optimisation technologies (using dendrimers to control where and when drugs go when introduced to the body) and Targeted Diagnostics (using dendrimers as a scaffold to which both location-signalling and targeting groups are added to allow location of specific cell type, such as cancer cells). More broadly the company is exploring dendrimer opportunities in materials science with applications as diverse as adhesives, lubricants and water remediation.

The Company has recently made the following commercialisation announcements:

- February 2007 - Starpharma signed an agreement with EMD/Merck Biosciences for laboratory applications of Profect[™], an RNAi transfection reagent. Starpharma has retained all therapeutic applications of this siRNA delivery technology and is actively seeking partners to develop products based on it.
- July 2007 - Starpharma announced that it had signed an agreement with a leading condom company in relation to the use of VivaGel[®] as a condom coating. The agreement includes a program of evaluation and development and also commercialisation rights covering condoms with VivaGel[®] coatings within a specified geographical region.
- October 2007 - Starpharma announced the signing of an agreement with SSL International plc (LSE:SSL), the world's largest manufacturer of condoms, and owner of Durex[®], the world's leading condom brand. The agreement, under which a commercial licence will be negotiated, sets out a co-development program for condoms with a VivaGel[®] coating.
- December 2007 - Starpharma announced the signing of a collaborative research agreement with Stiefel Laboratories, Inc., the world's largest independent pharmaceutical company specializing in dermatology, to

apply Starpharma's dendrimer nanotechnology to certain drugs used dermally. The collaboration will apply Starpharma's dendrimer technology to deliver drugs through the skin with the aim of improving the effectiveness and tolerability of certain dermal treatments.

SPL has a comprehensive IP portfolio that comprises more than 224 patents/applications issued and pending across 56 patent families - a unique level of IP concentration among nanotechnology companies.

Dendrimers: A type of precisely-defined, branched nanoparticle. Dendrimers have applications in the medical, electronics, chemicals and materials industries.

American Depository Receipts (ADRs): Starpharma's ADRs trade under the code **SPHRY** (CUSIP number 855563102). Each Starpharma ADR is equivalent to 10 ordinary shares of Starpharma as traded on the Australian Stock Exchange. The Bank of New York Mellon is the depository bank. Starpharma's ADRs are listed on International OTCQX (www.otcqx.com), a premium market tier in the U.S. for international exchange-listed companies, operated by Pink Sheets, LLC.

Forward Looking Statements

This document contains certain forward-looking statements, relating to Starpharma's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.

For further information:

Media Buchan Consulting		Starpharma www.starpharma.com	
Rebecca Wilson	Ellie Papatnasiou	Dr Jackie Fairley	Ben Rogers
Tel: +61 2 9237 2800 Mob: +61 417 382 391 rwilson@bcg.com.au	Tel: +61 2 9237 2800 epapatnasiou@bcg.com.au	Chief Executive Officer +61 3 8532 2704	Company Secretary +61 3 8532 2702 ben.rogers@starpharma.com